AKT1 and diabetic cardiomyopathy: It has been noted that the modulation of the PI3K/AKT pathway was informed to be a significant effector of Carva’s action to antagonize the renal toxicity induced by cisplatin (a well-known chemotherapeutic drug) [23] Furthermore, Liu et al. documented that Carva can ameliorate diabetic cardiomyopathy in experimental rats through regulating the PI3K/AKT pathway [24].